Pregabalin for neuropathic pain based on recent clinical trials. Export

@article{citeulike:5771627, abstract = {Pregabalin is a ligand for the alpha-2-delta subunit of voltage-gated calcium channels with anticonvulsant, analgesic, and anxiolytic properties. It has predictable absorption across the gastrointestinal tract, is neither metabolized nor protein-bound, and has minimal drug-drug interactions. It is effective with two or three-times daily dosing in a dose range of 150 to 600 mg daily. Seven published prospective, randomized clinical trials in postherpetic neuralgia (PHN) and painful diabetic peripheral neuropathy (DPN) demonstrate pain relief, decreased sleep interference, and improvements in several secondary outcome measures. The 50\% responder rates for PHN and DPN compare favorably with other first-line agents for neuropathic pain. Pregabalin is well tolerated in most patients with infrequent severe adverse effects. Pregabalin is an important addition to the treatment armamentarium for neuropathic pain.}, author = {Stacey, Brett R. and Swift, Jon N.}, citeulike-article-id = {5771627}, citeulike-linkout-0 = {http://view.ncbi.nlm.nih.gov/pubmed/18778571}, citeulike-linkout-1 = {http://www.hubmed.org/display.cgi?uids=18778571}, issn = {1531-3433}, journal = {Current pain and headache reports}, keywords = {pregabalin}, month = {June}, number = {3}, pages = {179--184}, posted-at = {2009-09-10 23:37:11}, priority = {2}, title = {Pregabalin for neuropathic pain based on recent clinical trials.}, url = {http://view.ncbi.nlm.nih.gov/pubmed/18778571}, volume = {10}, year = {2006} }

TY - JOUR ID - citeulike:5771627 L3 - citeulike-article-id:5771627 N2 - Pregabalin is a ligand for the alpha-2-delta subunit of voltage-gated calcium channels with anticonvulsant, analgesic, and anxiolytic properties. It has predictable absorption across the gastrointestinal tract, is neither metabolized nor protein-bound, and has minimal drug-drug interactions. It is effective with two or three-times daily dosing in a dose range of 150 to 600 mg daily. Seven published prospective, randomized clinical trials in postherpetic neuralgia (PHN) and painful diabetic peripheral neuropathy (DPN) demonstrate pain relief, decreased sleep interference, and improvements in several secondary outcome measures. The 50% responder rates for PHN and DPN compare favorably with other first-line agents for neuropathic pain. Pregabalin is well tolerated in most patients with infrequent severe adverse effects. Pregabalin is an important addition to the treatment armamentarium for neuropathic pain. IS - 3 JF - Current pain and headache reports SN - 1531-3433 EP - 184 TI - Pregabalin for neuropathic pain based on recent clinical trials. VL - 10 SP - 179 KW - pregabalin AU - Stacey, Brett AU - Swift, Jon PY - 2006/06// UR - http://view.ncbi.nlm.nih.gov/pubmed/18778571 ER -